Wall Street Zen downgraded shares of Cogent Biosciences (NASDAQ:COGT – Free Report) from a hold rating to a sell rating in a research note issued to investors on Saturday,Wall Street Zen reports.
COGT has been the topic of a number of other reports. Piper Sandler lifted their target price on Cogent Biosciences from $52.00 to $55.00 and gave the stock an “overweight” rating in a research report on Monday, August 17th. Wedbush reaffirmed an “outperform” rating and issued a $55.00 price target on shares of Cogent Biosciences in a report on Friday, May 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cogent Biosciences in a research report on Wednesday, July 8th. Finally, Guggenheim boosted their price objective on Cogent Biosciences from $45.00 to $52.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Cogent Biosciences has an average rating of “Moderate Buy” and an average target price of $51.56.
Read Our Latest Report on Cogent Biosciences
Cogent Biosciences Price Performance
Cogent Biosciences (NASDAQ:COGT – Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The technology company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.03. Analysts expect that Cogent Biosciences will post -2.25 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC raised its holdings in shares of Cogent Biosciences by 1,164.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 708 shares of the technology company’s stock worth $25,000 after buying an additional 652 shares in the last quarter. J.Safra Asset Management Corp bought a new stake in Cogent Biosciences in the second quarter valued at $27,000. Osaic Holdings Inc. raised its stake in Cogent Biosciences by 41.4% during the second quarter. Osaic Holdings Inc. now owns 4,550 shares of the technology company’s stock worth $33,000 after acquiring an additional 1,333 shares in the last quarter. Strs Ohio bought a new position in shares of Cogent Biosciences during the first quarter valued at $36,000. Finally, Global Retirement Partners LLC bought a new position in shares of Cogent Biosciences during the fourth quarter valued at $37,000.
About Cogent Biosciences
Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.
The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.
Read More
- Five stocks we like better than Cogent Biosciences
- 3 Under-the-Radar Defense Stocks With Record Backlogs
- This Korea ETF Has Soared, But the Rally May Not Be Over
- Why Guidewire’s Post-Earnings Plunge May Not Last
- Ride-Share Reckoning: Tesla Drives Into Uber’s Lane
Receive News & Ratings for Cogent Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogent Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
